Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry.

Details

Serval ID
serval:BIB_27E4D0CA2FC3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry.
Journal
Journal of the European Academy of Dermatology and Venereology
Author(s)
Cazzaniga S., Anzengruber F., Augustin M., Boehncke W.H., Borradori L., Conrad C., Cozzio A., Djamei V., French L.E., Gilliet M., Häusermann P., Heidemeyer K., Itin P., Kolios AGA, Laffitte E., Maul J.T., Mainetti C., Naldi L., Navarini A.A., Rustenbach S.J., Simon D., Sorbe C., Streit M., Yawalkar N.
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Publication state
Published
Issued date
12/2019
Peer-reviewed
Oui
Volume
33
Number
12
Pages
2313-2318
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Several treatment options are currently available for the treatment of psoriasis.
To explore the main associations between patients' characteristics and systemic treatments prescribed for psoriasis in a large group of patients observed in real-life clinical practice.
This was a retrospective analysis of baseline data collected within the Swiss Dermatology Network for Targeted Therapies registry in Switzerland between March 2011 and December 2017. Semantic map analysis was used in order to capture the best associations between variables taking into account other covariates in the system.
A total of 549 patients (mean age 46.7 ± 14.7 years) were included in the analysis. Conventional therapies such as retinoids and methotrexate were associated with no previous systemic therapies for psoriasis, a moderate quality of life (QoL) at therapy onset and older age (≥60 years). Fumaric acid derivatives were associated with mild psoriasis (psoriasis area severity index < 10) and long disease duration (≥20 years). On the other side, cyclosporine and psoralen and ultraviolet A/ultraviolet B treatments were linked to a more severe condition, including impaired QoL, hospitalization and inability to work. Regarding biological therapies, both infliximab and adalimumab were connected to the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. Etanercept, ustekinumab and secukinumab were all connected to a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education.
The analysis shows multifaceted associations between patients' characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, our semantic map indicates that comorbidities play a central role in decision-making of systemic treatments usage for psoriasis. Future studies should further investigate specific connections emerging from our data.
Keywords
Adult, Algorithms, Dermatologic Agents/therapeutic use, Female, Humans, Male, Middle Aged, Psoriasis/drug therapy, Psoriasis/physiopathology, Registries, Switzerland
Pubmed
Web of science
Create date
02/10/2019 16:16
Last modification date
20/04/2024 5:57
Usage data